Anuh Pharma Ltd (ANUHPHR)

Healthcare · Pharmaceuticals · NSE · Updated 17 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹89.42 ↑ 2.5% (1Y)

🎯 Key Takeaways

Anuh Pharma Ltd is a mature, cash-generative pharmaceutical company operating in a stable segment of the Indian market, with consistent profitability and strong returns on capital. Despite flat revenue trends and modest growth, the company maintains healthy margins, low leverage, and a disciplined capital allocation strategy.
Revenue declined 4.1% QoQ to ₹194 in Q1FY27.
⚠️ Margin compression in core operations, with EBITDA margin declining from 8.3% to 7.2% over four quarters, may reflect pricing pressure or input cost i

Market Cap

₹896

P/E Ratio

20.3

P/B Ratio

2.54

ROE

12.5%

ROCE

17.2%

Debt/Equity

0.00

Div Yield

1.68%

Promoter

71.8%

✨ Ask AI About ANUHPHR 📊 Interactive Charts

📖 The Story

Anuh Pharma Ltd is a mature, cash-generative pharmaceutical company operating in a stable segment of the Indian market, with consistent profitability and strong returns on capital. Despite flat revenue trends and modest growth, the company maintains healthy margins, low leverage, and a disciplined capital allocation strategy. Management prioritizes shareholder returns through regular dividends while navigating regulatory and governance updates. The business appears to be in a steady-state phase, focused on operational efficiency rather than aggressive expansion.

📰 What's Happening

Management has maintained a consistent focus on governance and shareholder communication over the past three quarters, with key filings centered around the FY2025-26 audited results, AGM outcomes, and compliance with SEBI norms. The company reappointed key directors including Arun Todarwal and appointed new quality leadership, signaling continuity in leadership. Shareholders approved a ₹1.50 per share dividend (30% payout) and ratified cost auditor remuneration, reflecting confidence in financial stewardship. Additionally, the company initiated shareholder outreach via email to distribute the annual report and encourage dematerialization of holdings, aligning with regulatory expectations.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	186	197	202	194
Operating Profit	9	16	17	14
OPM %	4.8%	8.2%	8.3%	7.2%
Net Profit	8	13	12	11
EPS	₹0.76	₹1.34	₹1.17	₹1.14

Operating margins have slightly compressed from 8.3% in Q3 2025 to 7.2% in Q1 2026, despite stable revenue around ₹190–202 crores, indicating minor pressure on profitability. Net profit and EPS have declined modestly over the same period, from ₹13 crores to ₹11 crores, reflecting the margin trend. However, cash flow from operations remains robust at ₹4,824.66 crores annually, supporting dividend sustainability. The company’s financial profile remains resilient, but the lack of top-line growth suggests limited near-term upside from volume or pricing expansion.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue or margin expectations in the latest filings. However, the reappointment of directors and approval of revised remuneration for Joint Managing Directors suggest confidence in governance stability. The Board continues to prioritize dividend distribution, having declared ₹1.50 per share for FY2025-26. No new strategic initiatives, product launches, or capacity expansions were disclosed in recent filings, implying a focus on maintaining existing operations and compliance rather than aggressive growth.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	25	25	50	50
Reserves	278	301	277	302
Borrowings	14	11	0	0
Total Liabilities	434	507	509	557
Fixed Assets	46	58	61	57
Investments	98	106	71	84
Total Assets	434	507	509	557

The balance sheet remains extremely conservative, with zero debt and equity of ₹50 crores, while reserves have grown to ₹302 crores, indicating strong internal accumulation. Total assets have slightly increased to ₹557 crores, but cash and equivalents have declined from ₹1,955.73 lakhs to an unreported lower figure, with net cash flow turning negative at ₹-11 crores in the latest quarter. Capital allocation appears focused on dividend payouts rather than reinvestment, consistent with a mature, cash-generative business model.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2026
Operating	-3
Investing	+18
Financing	-26
Net Cash Flow	-11

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	71.8%	71.8%	71.8%	71.8%
FII	0.0%	0.0%	0.1%	0.0%
DII	0.0%	0.0%	0.0%	0.0%
Public	23.9%	23.7%	23.6%	23.5%
# Shareholders	28,250	27,889	27,425	27,484

Promoter holding remains stable at 71.8% over the past year, with no significant changes in FII or DII participation, which remains negligible. The public shareholding base has slightly contracted, from 28,250 shareholders in Q2FY26 to 27,484 in Q1FY27, but remains broad. No promoter pledging or selling activity is evident, and institutional interest is minimal, suggesting limited analyst or fund coverage. The shareholder base is largely stable and retail-dominated.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.45 L Cr	36.8	18.7%	14.6%	0.05
DIVISLAB	2.44 L Cr	83.5	23.0%	17.4%	0.00
TORNTPHARM	1.83 L Cr	76.9	15.1%	25.7%	1.76
ZYDUSLIFE	1.10 L Cr	24.6	16.8%	16.6%	0.43
CIPLA	1.10 L Cr	32.6	13.2%	9.8%	0.01
LAURUSLABS	1.03 L Cr	94.1	20.8%	20.6%	0.45
DRREDDY	95,591	29.6	10.1%	8.4%	0.17
AUROPHARMA	94,420	25.6	12.8%	9.8%	0.20
LUPIN	93,605	16.5	27.9%	24.7%	0.26
MANKIND	92,842	45.4	13.9%	12.7%	0.38

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. Margin compression in core operations, with EBITDA margin declining from 8.3% to 7.2% over four quarters, may reflect pricing pressure or input cost increases not fully passed on. 2. Minimal institutional ownership and low trading liquidity could lead to high volatility and limited investor interest. 3. Regulatory and governance updates, while routine, require shareholder action (e.g., MOA/AOA adoption) that could introduce procedural delays or governance uncertainty if contested. 4. Cash flow volatility, with negative net cash flow in the latest quarter despite strong annual OCF, may signal timing issues or working capital strain.

📋 Recent Filings

🧠 Analyst's Read

Anuh Pharma operates as a stable, dividend-paying pharmaceutical entity with strong returns and no debt, but lacks growth catalysts. Investors should monitor margin trends and shareholder activity around upcoming governance decisions, particularly related to charter changes and director compensation. The company’s future performance hinges on maintaining operational discipline rather than expansion.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on ANUHPHR

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ANUHPHR files new disclosures

Track ANUHPHR filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ANUHPHR — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd